-

05:31:25 AM

MGNX Stock News

MGNX - Macrogenics Inc

05/09/23 4:01 PM

Nasdaq : MGNX

earnings

MacroGenics Provides Update on Corporate Progress and First Quarter 2023 Financial Results

ZYNYZ™ is third product approved in U.S. that originated from MacroGenics' pipeline Multiple Phase 2 programs advancing in metastatic castration-resistant prostate cancer (mCRPC) Cash runway through 2025 with $270 million in non-dilutive funding achieved over past nine months Conference call

RHEA-AI

neutral

05/04/23 4:30 PM

Nasdaq : MGNX

earnings

MacroGenics Announces Date of First Quarter 2023 Financial Results Conference Call

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial

RHEA-AI

neutral

04/24/23 6:15 PM

Nasdaq : MGNX

conferences

MacroGenics to Participate in Upcoming Investor Conferences

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the

RHEA-AI

neutral

03/22/23 1:22 PM

Nasdaq : MGNX

fda approval

MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ™ (retifanlimab-dlwr)

MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today reported that following the U.S. Food and Drug Administration’s

RHEA-AI

very positive

03/15/23 4:01 PM

Nasdaq : MGNX

earnings

MacroGenics Provides Corporate Update and 2022 Financial Results

Cash runway extended through 2025 with $ 250 million in non-dilutive funding over past eight months TAMARACK study design modified with objective of accelerating data readout Encouraging lorigerlimab (PD-1 × CTLA-4 bispecific DART ® molecule) monotherapy clinical data presented at ASCO-GU

RHEA-AI

positive

03/14/23 8:14 AM

Nasdaq : MGNX

Synaffix Announces Expansion of ADC Collaboration with MacroGenics

Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates with best-in-class therapeutic index, has announced the expansion of its license agreement with MacroGenics Inc., a biopharmaceutical company focused on developing and commercializing...

RHEA-AI

positive

03/08/23 5:36 PM

Nasdaq : MGNX

MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that it has entered into an agreement to sell

RHEA-AI

neutral

03/07/23 6:00 PM

Nasdaq : MGNX

earnings

MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial

RHEA-AI

neutral

03/02/23 4:30 PM

Nasdaq : MGNX

conferences

MacroGenics to Participate in Upcoming Investor Conferences

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the

RHEA-AI

neutral

02/13/23 5:20 PM

Nasdaq : MGNX

clinical trial

MacroGenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients with Metastatic Castration-Resistant Prostate Cancer to be Presented at ASCO Genitourinary Cancers Symposium

Twelve of 42 patients (28.6%) in metastatic castration-resistant prostate cancer (mCRPC) cohort achieved ≥ 50% prostate-specific antigen (PSA) reduction (PSA50), including 9 (21.4%) who achieved ≥ 90% PSA reduction (PSA90) Nine of 35 patients (25.7%) with measurable mCRPC achieved confirmed partial

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 Next

MGNX Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.macrogenics.com
CeoScott Koenig
Security nameMacrogenics Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees357
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address9704 Medical Center Dr
StateMaryland
CityRockville
Zip20850-3343
CountryUS
Phone13012515172

About Macrogenics Inc

MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.